C-Suite Shuffle: Bayer Continues Leadership Shakeup with Hires at Subsidiaries 4/17/2024

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2) The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.

The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen.

J&J Narrowly Misses Q1 Revenue on Lower-Than-Expected Stelara Sales 4/16/2024

Sandoz’s Biosimilar Skyrockets After CVS Removes AbbVie’s Humira from Formularies 4/16/2024

Boehringer Ingelheim Aims to Bring 25 New Products to Market by 2030 4/16/2024

Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review 4/16/2024

Intra-Cellular Touts Phase III Major Depressive Disorder Results for Antipsychotic Drug 4/16/2024

Ultragenyx Eyes Pivotal Study After Mid-Stage Win in Angelman Syndrome 4/16/2024

Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit 4/16/2024

Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumor. However, ASOs aren’t used for treating cancer yet. They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge. Cancer cells have gatekeeper molecules that stop unwanted substances from entering.

FDA Puts Clinical Hold on Neumora’s Schizophrenia Drug Due to Preclinical Saf... 4/15/2024

Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion 4/15/2024

FDA Adcomm Backs New Surrogate Endpoint for Accelerated Approvals in Blood Cancer 4/15/2024

AbbVie Touts Long-Term Efficacy of Qulipta as Preventive Migraine Treatment 4/15/2024

Genentech Walks Away From $3B Allogeneic T-Cell Pact with Adaptimmune 4/15/2024

Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech 4/15/2024

Listen Up: Emerging Vocal Biomarker Could Aid ALS Drug Development 4/15/2024

5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra 4/15/2024

4 Investigational Weight Loss Drugs That Could Change the Market 4/15/2024

Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine.

This combined approach, developed by Florida International University cancer researcher Diana Azzam, was used successfully for the first time to guide treatment of relapsed pediatric cancer patients in collaboration with First Ascent Biomedical and Dr. Maggie Fader at the Helen & Jacob Shaham Cancer & Blood Disorders Institute at Nicklaus Children's Hospital in Miami.